Verona Pharma
Who owns Verona Pharma?
Verona Pharma is a British Biotech company, now owned by Merck, which acquired it in 2025 from Sofinnova Partners and Abingworth.
Hand-verified · updated 2026-04-21
Open JSON · CC-BY
Key facts
- ·Fully exited in 2025 to Merck (MSD).
- ·Average hold across 2 realized cycles: 4 years.
Ownership history
3 ownership periods
Andera Partners exited Verona Pharma in 2017 via Trade Sale after 1 year.
Sofinnova Partners sold Verona Pharma to Merck in 2025 after 6 years.
Abingworth sold Verona Pharma to Merck & Co. in 2025.
More from Sofinnova Crossover Fund I
Other portfolio companies in the same fund.
France
United Kingdom· 2026
France· 2021
UK· 2021UK· 2020
Sweden· 2020More PE-backed in Biotech
Comparable biotech deals from other GPs.
USQuestions
Who owns Verona Pharma?
Verona Pharma is now owned by Merck, which acquired it in 2025 from Sofinnova Partners and Abingworth.
When did Merck acquire Verona Pharma?
Merck acquired Verona Pharma in 2025, buying from Sofinnova Partners and Abingworth.
Who did Verona Pharma sell to?
Sofinnova Partners sold Verona Pharma to Merck in 2025 (Trade Sale). Abingworth sold Verona Pharma to Merck & Co. in 2025 (Trade Sale).
Who has owned Verona Pharma over time?
Verona Pharma has been through 3 private-equity ownership periods: Andera Partners · via BioDiscovery 4 · 2016–2017 · (Trade Sale); Sofinnova Partners · via Sofinnova Crossover Fund I · 2019–2025 · sold to Merck · (Trade Sale); Abingworth · via Abingworth Bioventures VI · sold to Merck & Co. · (Trade Sale).